Biphasic (Premix) Insulin Analogs in Type 2 Diabetes Mellitus

Author: Mansour, Abbas A.

Source: Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Volume 2, Number 2, June 2008 , pp. 129-134(6)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $104.88 plus tax (Refund Policy)

Abstract:

One of the causes of failure to achieve target HbA1C in type 2 diabetes mellitus is delay in starting insulin .The standard insulin fails in large number because soluble insulin used for postprandial glucose control does not have a fast enough onset of action ; it needs to be given 30 and 45 minutes before meals ,and has an inappropriately prolonged duration of action, while the longer-acting zinc formulations do not have the long duration of action required of a basal insulin , even with biphasic human insulin. Biphasic insulin analogs allows delivery of both basal and prandial insulin in 1 injection that can be administered closer to mealtime, and produce greater reductions in the magnitude of postprandial glucose excursions than biphasic human insulin with less incidence of major hypoglycemia. The data in this review discuss related recent patents and highlights the importance of biphasic insulin analogs in the management of type 2 diabetes mellitus.

Keywords: Type 2 diabetes mellitus; insulin analogs; glycaemic control

Document Type: Research article

DOI: http://dx.doi.org/10.2174/187221408784534231

Publication date: 2008-06-01

More about this publication?

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery publishes review articles by experts on recent patents in the field of endocrine, metabolic and immune drug discovery e.g. on novel bioactive compounds, analogs & targets. A selection of important and recent patents in the field is also included in the journal. The journal is essential reading for all researchers involved in endocrine, metabolic and immune drug design and discovery.